Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada

Journal of the American Geriatrics Society

Volumn 47, Issue 5, 1999, Pages 570-578

  O'Brien, Bernie J ^a,b,e   Goeree, Ron ^a,b   Hux, Margaret ^c   Iskedjian, Michael ^c   Blackhouse, Gordon ^a,b   Gagnon, Michelle ^a   Gauthier, Serge ^d  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

^c i3 Global   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e ST JOSEPH S HOSPITAL   (Canada)

Author keywords

Alzheimer's disease; Cost effectiveness; Donepezil; Economics

Indexed keywords

DONEPEZIL;

ALZHEIMER DISEASE; ARTICLE; CANADA; COMMUNITY CARE; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; NURSING HOME;

EID: 0032959931     PISSN: 00028614     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1532-5415.1999.tb02572.x     Document Type: Article

References (25)

1. Ritchie K, Kildea D. Is senile dementia 'age related' or 'aging related'? Evidence from a meta-analysis of dementia prevalence in the oldest old. Lancet 1995;346:931-934.
2. Bachman DL, Wolf PA, Linn RT et al. Incidence of dementia and probable Alzheimer's disease in a general population: The Framingham Study. Neurology 1993;43:515-519.
3. Jorm AF. The Epidemiology of Alzheimer's Disease and Related Disorders, London: Chapman & Hall, 1990.
4. Canadian Study of Health and Aging Working Group. Canadian Study of Health and Aging: Study methods and prevalence of dementia. Can Med Assoc J 1994;150:899-913.
5. Hay JW, Ernst RL. The economic cost of Alzheimer's disease. Am J Public Health 1987;77:1169-1175.
6. Ernst RL, Hay AJ. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994;84:1261-1264.
7. Østbye T, Crosse E. Net economic costs of dementia in Canada. Can Med Assoc J 1994;151:1457-1464.
8. Rogers SL, Friedhoff LT. The efficacy and safety of donepezil in patients with Alzheimer's Disease: Results of a US multicentre, randomized, double-blind, placebo-controlled trial. Dementia 1996;7;293-303.
9. Rogers SL, Farlow MR, Doody RS, et al. A 24 week double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's Disease. Neurology 1998;50:136-145.
10. Small GW, Rabins PV, Bartels R et al. Diagnosis and treatment of Alzheimer's disease and related disorders. JAMA 1997;278:1363-1371.
11. Ontario Ministry of Health. Ontario Guidelines for Economic Analysis of Pharmaceutical Products, Toronto: Ontario Ministry of Health, 1994,
12. Tombaugh TN, McIntyre NJ. The Mini-Mental State Examination: A comprehensive review. J Am Geriatr Soc 1992;40:922-935.
13. Sonnenberg F, Beck JR. Markov models in medical decision making: A practical guide. Med Decis Making 1993;13:322-338.
14. Beck JR, Pauker SG. The Markov process in medical prognosis. Med Decis Making 1983;3:419-458.
15. Sox HC Jr, Blatt MA, Higgins MC, Marton KI. Medical Decision Making. Boston: Butterworth-Heinemann, 1988.
16. Weinstein MC, Fineberg HV. Clinical Decision Analysis. Philadelphia: W.B. Saunders, 1980.
17. Hogan DB, Thierer DE, Ebly EM, Parhad IM. Progression and outcome of patients in a Canadian dementia clinic. Can J Neurol Sci 1994;21:331-338.
18. Hux MJ, O'Brien BJ, Iskedjian M et al. Relation between severity of Alzheimer's disease and costs of caring. Can Med Assoc J 1998;159:457-465.
19. Drummond MF, O'Brien BJ, Stoddart GL, Torrance GW. Methods for the Economic Evaluation of Health Care Programmes, Oxford: Oxford University Press, 1997.
20. Henke CJ, Burchmore MJ. The economic impact of tacrine in the treatment of Alzheimer's disease. Clin Therapeut 1997;19:330-345.
21. Lubeck DP, Mazonson PD, Bowe T. The potential impact of tacrine on expenditures for Alzheimer's disease. Med Interface 1995;7:130-138.
22. Wimo A, Karlsson G, Nordberg A, Winblad B. Treatment of Alzheimer's disease with tacrine - a cost analysis model. Alzheimer's Dis Assoc Disord 1997;11:191-200.
23. Buxron MJ, Drummond MF, van Hout BA et al. Modelling in economic evaluation: An unavoidable fact of life. Health Econ 1997;6:217-227.
24. O'Brien B. Economic evaluation of pharmaceuticals: Frankenstein's monster or vampire of trials? Med Care 1996;34:DS99-108.
25. Yusuf S, Wittes J, Probstfield J, Tyroler HA. Analysis and interpretation of treatment effects in subgroups of patients in randomized clinical trials. JAMA 1991;266:93-98.